Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.

Fernández-García, D; Muñoz-Torres, M; Mezquita-Raya, P; de la Higuera, M; Alonso, G; Reyes-García, R; Ochoa, A Sebastian; Ruiz-Requena, M E; Luna, J Dios; Escobar-Jiménez, F

Fernández-García, D; Muñoz-Torres, M; Mezquita-Raya, P; de la Higuera, M; Alonso, G; Reyes-García, R; Ochoa, A Sebastian; Ruiz-Requena, M E; Luna, J Dios; Escobar-Jiménez, F.

Affiliation

Fernández-García D; Bone Metabolic Unit, Endocrinology Division, University Hospital San Cecilio Granada, RETICEF, Granada, Spain.

J Endocrinol Invest ; 31(5): 416-21, 2008 May.

Article in En | MEDLINE | ID: mdl-18560259

Subject(s)

Osteoporosis, Postmenopausal/blood; Osteoporosis, Postmenopausal/drug therapy; Osteoprotegerin/blood; RANK Ligand/blood; Raloxifene Hydrochloride/therapeutic use; Aged; Bone Density Conservation Agents/therapeutic use; Calcium/administration & dosage; Female; Humans; Middle Aged; Raloxifene Hydrochloride/administration & dosage; Vitamin D/administration & dosage

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Osteoporosis, Postmenopausal / Raloxifene Hydrochloride / RANK Ligand / Osteoprotegerin Limits: Aged / Female / Humans / Middle aged Language: En Journal: J Endocrinol Invest Year: 2008 Document type: Article

Search on Google

XML

PubMed Links